

REMARKS

The application is to be amended as previously set forth; amendments are being made in this document to incorporate the claims as amended in the PCT application of which this is a 371 application. The Preliminary Amendment mailed December 13, 2004, inadvertently utilized the claims as initially published in the International PCT Application. International Patent Application No. PCT/EP03/06341, of which the present application is a National Phase Entry, was amended on June 7, 2004, to include a new claim set. Therefore, the present Supplemental Preliminary Amendment replaces the claim amendment submitted with the Preliminary Amendment of December 13, 2004.

Support for new claims 29-51 can be found throughout the specification, for example, in claims 1-28. Support for the oligopeptide sequence being Xaa₁-Xaa₂-R-Xaa₃-Asp-Xaa₄, wherein the sequence is as defined in the claims, is found throughout the specification and sequence listing, for example, as shown in SEQ ID NOS:17-24, and SEQ ID NOS:25-28 (starting at about amino acid 97-99).

If questions remain after consideration of the foregoing, the Office is kindly requested to contact applicants' representative at the address or telephone number given herein.

Respectfully submitted,



G. Scott Dorland, Ph.D.
Registration No. 51,622
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922
Facsimile: 801-531-9168

Date: June 24, 2005